Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Braun, M S, Adab, F, Bradley, C, McAdam, K, Thomas, G, Wadd, N J, Rea, D, Philips, R, Twelves, C, Bozzino, J, MacMillan, C, Saunders, M P, Counsell, R, Anderson, H, McDonald, A, Stewart, J, Robinson, A, Davies, S, Richards, F J, Seymour, M T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394314/
https://www.ncbi.nlm.nih.gov/pubmed/14520437
http://dx.doi.org/10.1038/sj.bjc.6601237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394314/
https://www.ncbi.nlm.nih.gov/pubmed/14520437
http://dx.doi.org/10.1038/sj.bjc.6601237

Ejemplares similares